After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

Spread the love Introduction The world of science is vast and ever-evolving, with countless brilliant minds pushing the ...

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22.

Emmanuelle is recruited for a time-travel experiment that sends her to times and places where all her wishes are granted.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Four years ago, Emmanuelle Charpentier and Jennifer ... The team revealed that they would combine the CRISPR therapeutics and receptor-targeting reagents and move to preclinical models to study ...

Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Beam Therapeutics said Monday that ...